Belantamab mafodotin is now TGA-registered for people with multiple myeloma who have had at least one prior line of therapy. Available exclusively to CNSA members, we encourage you to login and listen today!
T-cell engagers, bispecifics and CAR-T are changing myeloma care fast. Two HSANZ events in Sydney and Adelaide will help you get up to speed, and the Adelaide seminar is free, with a virtual option.
Gain practical insights into understanding and responding to the evolving needs of people living with CML, from diagnosis through treatment and beyond.
As of 1 September 2026, nurse practitioners have been able to prescribe PBS-listed medicines for chronic myeloid leukaemia (CML) as a continuation of an existing therapy, where care is shared with a medical practitioner.
Cancer nurses working across haematology and cancer care can bring an important perspective to improving awareness and understanding of Bone Marrow Failure Syndromes. Maddie Riewoldt’s Vision is inviting healthcare professionals to complete a short national needs assessment and help shape future education.
eviQ has announced a brand new learning resource on Immune Effector Cell-associated Neurotoxicity (ICANS), aimed at health professionals involved in the care of patients receiving CAR T-cell or T-cell engaging therapies.
